| Key Takeaways |
1. India has five main categories of weight loss medicine, four widely available and two approved abroad but not yet in India. 2. The GLP-1 class (semaglutide and liraglutide) and the newer dual-hormone class (tirzepatide) have shown the largest weight loss effects in trial conditions with tirzepatide reaching a mean of 20.9% of body weight. 3. Orlistat, the oldest option in India, works through a different mechanism and shows a modest but consistent effect over years of use. 4. Every prescription weight loss medication in India has BMI eligibility criteria; none is prescribed for cosmetic weight loss. 5. Ayurvedic, homeopathic, and over-the-counter “fat burner” products are regulated differently and are not evidence-equivalent to prescription medicine. 6. Every medication in this article requires a doctor. Without medical supervision, dose titration, and lifestyle scaffolding, none of them reaches the effect the trials measured. |
India’s weight loss medicine landscape has changed more in the last eighteen months than in the previous eighteen years. Mounjaro launched in India in March 2025. Wegovy followed in June 2025. Ozempic arrived in December 2025. When semaglutide’s Indian patent expired on 20 March 2026, more than forty generic manufacturers filed to enter the market.
For anyone considering medication for weight loss, this is both useful news and confusing news. There are more options, more brands, and more marketing noise than at any point before. The honest question is not which medicine has the biggest headline number. The honest question is which medicine fits which situation and what each one actually does when the trial data is read plainly.
This guide walks through every weight loss medication currently relevant in India, groups them by how they work, states what the peer-reviewed research shows about each, and closes with the one thing every single one of them shares: none of them delivers its studied effect without a doctor.
What Actually Counts as a Weight Loss Medication?
Not every product marketed for weight loss is medicine. In the Indian pharmacy landscape, three very different categories often get lumped under the same shelf.
Prescription medications are drugs approved by the Central Drugs Standard Control Organisation (CDSCO) for the specific indication of weight management, backed by phase 3 clinical trials and dispensed only against a doctor’s prescription. Everything covered in the rest of this guide falls into this category.
Over-the-counter supplements and traditional formulations (Ayurvedic, homeopathic, herbal blends, and “fat burner” tablets) are regulated differently. They are not required to demonstrate weight loss efficacy through the same trial framework required of pharmaceuticals. Most rely on traditional use, small studies or manufacturer testimonials. Their availability without prescription is a regulatory category, not a signal of clinical equivalence.
Repurposed medications are drugs approved for something else where weight change is a documented side effect. Metformin, prescribed for type 2 diabetes and polycystic ovary syndrome, is the most common example.
These distinctions matter because comparing them as if they were interchangeable is misleading.
When Is Medication Even a Question?
Before comparing what each medicine does, the eligibility question matters. In India, overweight and obesity are defined at lower thresholds than in most Western countries, because South Asian bodies accumulate metabolically harmful fat at lower BMIs.
The 2025 Indian obesity guidelines redefined the local cut-offs: overweight now begins at a BMI of 23 and obesity at 25, compared with the older global defaults of 25 and 30. Abdominal obesity is defined at a waist of 90 cm in men and 80 cm in women.
According to the ICMR-INDIAB study, an estimated 254 million Indian adults live with generalised obesity and 351 million with abdominal obesity. These numbers are why weight loss medication has moved from a niche question to a mainstream one across metros and smaller cities alike.
Global drug labels for GLP-1 medications typically list a BMI of 30 or above, or 27 with a weight-related condition. Indian clinical practice increasingly applies the local thresholds. The eligibility question is answered in a doctor’s consulting room, not at a pharmacy counter.
The Fat Absorption Blocker: What Does Orlistat Do?
Orlistat is the oldest weight loss medication still in widespread Indian use, approved by the US FDA in 1999 and available in India for over two decades. It is sold under brand names including Xenical, Reeshape, O-Stat, and dozens of generic versions from Indian manufacturers.
The mechanism is different from every other drug in this guide. Orlistat blocks pancreatic and gastric lipases in the digestive tract, preventing roughly 30% of dietary fat from being absorbed. The unabsorbed fat is excreted in stool.
The side effect profile is largely gastrointestinal and directly tied to the mechanism. Because unabsorbed fat is excreted, users may experience oily stools, urgent bowel movements, flatulence with discharge, and abdominal discomfort, especially after high-fat meals. These effects typically ease as dietary fat intake adjusts, and are one reason orlistat pairs naturally with a lower-fat eating pattern.
At the 120 mg dose used in most Indian prescriptions, orlistat is prescription-only. A lower 60 mg dose is available over the counter in some markets under the name Alli, though this is not widely sold in India.
The Single-Hormone GLP-1 Medicines: What Are Liraglutide and Semaglutide?
The GLP-1 receptor agonist class is the reason weight loss medication is in the news. These drugs mimic glucagon-like peptide-1, a hormone the intestine releases after eating. GLP-1 signals fullness to the brain, slows the rate at which the stomach empties, and improves how the body handles insulin. Higher, sustained levels of this signal reduce appetite substantially in most users.
Liraglutide was the first GLP-1 medicine approved for weight management. It is sold as Saxenda for obesity (3.0 mg daily injection) and Victoza for type 2 diabetes (up to 1.8 mg daily injection).Saxenda has limited availability in India; Victoza is widely available for diabetes.
Semaglutide is the same drug class, chemically related to liraglutide but with a longer half-life that allows once-weekly rather than daily injection. It is sold in India under three brand names for different indications: Ozempic (weekly injection up to 2.0 mg, approved for type 2 diabetes), Wegovy (weekly injection at 2.4 mg, approved for chronic weight management), and Rybelsus (an oral tablet at 3, 7, or 14 mg, approved for type 2 diabetes).
The Dual-Hormone Medicine: What Is Tirzepatide?
Tirzepatide, sold in India as Mounjaro and launched by Eli Lilly on 20 March 2025, is the newest widely-used weight loss medication in the country. It differs from the GLP-1 medicines by activating two receptors simultaneously: the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual mechanism is why it is described as a single-molecule dual agonist.
Mounjaro became India’s top-selling drug by revenue within seven months of launch. This is a market observation, not a clinical endorsement. The choice between GLP-1 or dual-hormone medicines is a clinical decision that considers baseline weight, coexisting conditions, tolerability, injection preference, and access. A prescribing doctor weighs these factors; market share does not.
The Combination Oral Medicines: What About Contrave and Qsymia?
Two other prescription medications approved abroad appear frequently in Indian search results, so a plain word on both is useful.
Contrave is a fixed-dose combination of naltrexone (an opioid receptor blocker) and bupropion (an antidepressant that also reduces cravings). It was approved by the US FDA in 2014 for chronic weight management. Its mechanism affects appetite regulation and food reward pathways in the brain. Contrave is not currently approved or marketed in India.
Qsymia is a combination of phentermine (an appetite suppressant) and topiramate (an anticonvulsant with weight loss side effects). It is FDA-approved for chronic weight management. Phentermine is a restricted substance in India, and Qsymia is not available domestically.
The frequent appearance of these names in Indian searches reflects overseas availability and pharmaceutical curiosity rather than practical Indian options. Importing or ordering them without a valid Indian prescription is legally fraught and clinically unsupervised and the doses and formulations sold online often bypass the trial-tested dose titration that made the drugs safe in the first place.
The Repurposed Medicine: Does Metformin Cause Weight Loss?
Metformin is the most commonly prescribed medication for type 2 diabetes in India, and it is also widely used off-label for polycystic ovary syndrome. It is not approved as a weight loss medication. The mechanism is not fully understood but appears to involve reduced appetite, improved insulin sensitivity, and changes to gut microbial composition.
Metformin is a reasonable option for a doctor to consider in specific clinical situations: insulin resistance, prediabetes, PCOS with metabolic features, or type 2 diabetes with a weight component. The weight change is modest and secondary. Prescribing metformin for weight loss alone in someone without these conditions is not standard practice.
What About Ayurvedic Tablets, Homeopathic Medicines and Fat Burner Supplements?
The Indian market is dense with alternative and over-the-counter products marketed for weight loss. Patanjali, other Ayurvedic manufacturers, homeopathic clinics, and independent supplement brands offer tablets, capsules, powders and teas with weight loss claims. Their volume in the market is substantial, so leaving them out of a plain guide would be dishonest.
The regulatory and evidentiary framework for these products is not the same as prescription medicine. They are not required to demonstrate weight loss efficacy through the phase 3 randomised controlled trials required of pharmaceuticals. Most claims rest on traditional use, small open-label studies or manufacturer testimonials rather than the peer-reviewed trial evidence cited elsewhere in this guide.
This does not automatically mean these products do nothing. It does mean that any comparison to prescription weight loss medication is not evidence-equivalent, and that side effect profiles and drug interactions may not be systematically studied.
Anyone considering these products should tell their doctor. Combinations with prescription medications for diabetes, blood pressure, thyroid conditions, or blood thinners can produce real consequences that neither the pharmacy nor the person taking them may anticipate.
What Happens If You Stop Taking the Medication?
This is one of the most important questions and it applies to every medication in this guide.
This is not a failure of the medication. It is the nature of obesity. The biological drivers that produced the weight in the first place (appetite hormones, insulin dynamics, metabolic set point) return to their previous state when the medication that was blunting them stops. Similar rebound patterns are seen with orlistat and liraglutide upon discontinuation and are expected with tirzepatide.
The practical implication is unavoidable: weight loss medication is not a short course of treatment for a one-time problem. It is treatment for a chronic condition and the treatment plan has to reflect that. Deciding whether, when, and how to stop is a medical conversation, not a personal one.
Who Should Not Take These Medications?
Every weight loss medication has contraindications, and some apply broadly across the categories described above.
Pregnancy and breastfeeding rule out all of these medicines. A personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia type 2, is a specific contraindication for the GLP-1 and dual-hormone classes. Orlistat is not recommended in people with chronic malabsorption syndromes or cholestasis.
Severe gastroparesis, active or prior pancreatitis, and uncontrolled psychiatric conditions each require careful case-by-case assessment. A history of eating disorders raises specific concerns that a prescribing doctor must weigh, because appetite-suppressing medicines can interact badly with disordered eating patterns.
This is not an exhaustive list, which is precisely the point. Whether a specific medicine is safe for a specific person is a clinical assessment based on that person’s full medical picture, not a rule that can be read off a pharmacy shelf.
What Every One of These Medicines Actually Requires
Every medication in this guide, from decades-old orlistat to the newest tirzepatide, shares one thing: none of them delivers its studied effect without medical supervision.
The Schedule H and Schedule H1 categories under India’s Drugs and Cosmetics Rules exist for exactly this reason. Selling or dispensing these medicines without prescription is illegal, and the classification acknowledges that safety and effect depend on the drug being prescribed and monitored, not simply consumed.
This is also the reason medically supervised programmes exist. The medicine itself is one variable. The doctor, the eating and movement plan around it, the dose titration schedule, the side effect management, the periodic laboratory work and the accountability structure make the rest of the difference between a trial-quality outcome and a disappointing one.
| Bottom Line |
| India now has more prescription weight loss medication options than at any point in its history, from decades-old orlistat to next-generation dual-hormone injectables. Every one of these medications is a prescription-only tool that reaches its studied effect only under medical supervision, structured lifestyle change, and honest ongoing monitoring. The right question is which medicine is right for your specific medical situation and what the plan around it needs to look like to actually work. |
Frequently Asked Questions
Q1. Which weight loss medications are available in India right now?
As of late 2026, the prescription weight loss medications available in India include orlistat (Xenical, Reeshape, O-Stat, and multiple generics), tirzepatide (Mounjaro), semaglutide for chronic weight management at 2.4 mg (Wegovy) and semaglutide for type 2 diabetes at lower doses (Ozempic as a weekly injection, Rybelsus as an oral tablet). Liraglutide is widely available for diabetes as Victoza, with more limited availability of Saxenda for obesity. Following the March 2026 patent expiry, numerous generic versions of semaglutide from Indian manufacturers such as Sun Pharma, Dr Reddy’s, Cipla, Natco, Lupin, and Alkem are also on the market.
Q2. Do you need a prescription for weight loss medicine in India?
Yes. Every medication named in this article is classified as prescription-only under India’s drug regulations. Buying or importing these medicines without a valid Indian prescription is illegal and it also skips the medical supervision that the trial data assumes. The stated efficacy figures come from studies where a clinician was involved throughout; self-directed use is not the same intervention.
Q3. Can weight loss medication work without diet and exercise?
No trial in the peer-reviewed literature has tested weight loss medication in isolation from lifestyle change. Every efficacy figure cited for these drugs came from studies where participants also received structured guidance on diet and physical activity. Medication is designed to complement lifestyle changes by making them easier to sustain, not to replace them.
Q4. Are these medications safe to take long term?
Long-term safety data varies by molecule. Orlistat has over two decades of use and a well-characterised side effect profile. GLP-1 medicines have accumulated long-term data demonstrating cardiovascular benefit in a large cohort with established cardiovascular disease. Tirzepatide has shorter-duration data because it is newer. All of them require ongoing medical monitoring for side effects, laboratory changes and interactions with other medications a person is already taking.
Q5. What is the difference between weight loss tablets and injections?
The primary difference is the medication itself, not the format. Orlistat is a tablet that works in the gut to block fat absorption. Rybelsus is a semaglutide tablet that works on appetite through the GLP-1 pathway. Wegovy, Ozempic, Mounjaro, Saxenda, and Victoza are injectables that work on the same appetite pathways.
Injectable medications in this class have generally shown larger mean weight loss effects at their approved obesity doses than currently approved oral options, but individual response varies substantially and the choice depends on medical assessment of the specific person.
| Medical Disclaimer |
| This article is educational and does not constitute medical advice, diagnosis, or treatment. Every weight loss medication mentioned is prescription-only in India and requires assessment, prescription, and ongoing monitoring by a qualified medical doctor. Do not start, stop, switch, or change the dose of any medication based on information in this article. Consult a licensed medical professional before making any decision about weight loss treatment. |
